Armata reports Q3 2026 results; net income driven by convertible loan fair value gain
Armata Pharmaceuticals reported grant and award revenue of $3.171 million for the three months ended September 30, 2026 versus $1.159 million in the comparable 2025 period, and a loss from operations of $7.383 million compared with a $7.776 million loss a year earlier. Net income was $54.857 million ($1.15 basic; $(0.24) diluted), primarily driven by a $69.595 million non-cash gain from the change in fair value of the convertible loan, versus a $26.675 million net loss in the comparable 2025 period. Nine-month r...
Key takeaways
Grant and award revenue: $3.171 million in Q3 2026 versus $1.159 million in Q3 2025 (+173.6%); nine-month revenue of $6.470 million versus $3.819 million (+69.4%), representing the Medical Technology Enterprise Consortium's share of AP-SA02 program costs.
Operating loss narrowed: $7.383 million loss versus $7.776 million loss in Q3 2025, with R&D up 17.3% to $6.830 million and G&A up 19.7% to $3.724 million; nine-month operating loss was $26.480 million versus $22.811 million.
Net income of $54.857 million for Q3 2026 ($1.15 basic EPS; $(0.24) diluted EPS), primarily driven by a $69.595 million gain from the change in fair value of the convertible loan, versus a $26.675 million net loss in Q3 2025; income attributable to participating warrants was $12.219 million, leaving $42.638 million attributable to common stockholders.
Balance sheet: cash and cash equivalents of $18.317 million at September 30, 2026 versus $8.688 million at December 31, 2025; convertible loan of $94.309 million and term debt of $83.862 million reclassified to current, total liabilities of $258.606 million, and a total stockholders' deficit of $(174.128) million.
Cash flow: nine-month net cash used in operating activities of $19.964 million versus $19.089 million; financing provided $28.494 million including $25.000 million of term debt issuance proceeds and $2.373 million from common stock sold under the ATM; nine-month EPS was $0.29 basic and $(0.74) diluted.
AP-SA02 Phase 3 program: FDA Breakthrough Therapy designation received, agreed Initial Pediatric Study Plan obtained with pediatric studies deferred, four AP-SA02 engineering runs completed and one cGMP production run and vialing completed in the third quarter of 2026, with Phase 3 superiority study initiation expected in the second half of 2026 depending on FDA concurrence with the protocol.
Funding: received $3.7 million of additional non-dilutive funding from the U.S. Department of War, the first funds received specifically for AP-SA02 Phase 3 execution, bringing cumulative non-dilutive DoW funding under the award to approximately $32.4 million including $28.7 million previously provided.
Key metrics
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow ARMP in real time
Get material earnings, filing, IR, and earnings-call alerts by email.